Form 8-K - Current report:
SEC Accession No. 0000950170-22-026823
Filing Date
2022-12-20
Accepted
2022-12-20 16:07:11
Documents
12
Period of Report
2022-12-19
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K stro-20221219.htm   iXBRL 8-K 55068
  Complete submission text file 0000950170-22-026823.txt   174115

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT stro-20221219_lab.xml EX-101.LAB 13654
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT stro-20221219_pre.xml EX-101.PRE 10994
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT stro-20221219.xsd EX-101.SCH 2464
6 EXTRACTED XBRL INSTANCE DOCUMENT stro-20221219_htm.xml XML 4752
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 221474815
SIC: 2836 Biological Products, (No Diagnostic Substances)